WBA - What's Going On European Pharma Giant AstraZeneca Stock On Wednesday? | Benzinga
Wednesday, Japan approved AstraZeneca Plc (NASDAQ:AZN) and Sanofi SA’s (NASDAQ:SNY) Beyfortus (nirsevimab), a long-acting monoclonal antibody for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in all neonates, infants and children.
Beyfortus is anticipated to be available for the upcoming 2024/25 RSV season, which is in line with existing Japanese guidelines.
More than 100,000 cases of RSV LRTD in infants are reported every year in Japan, including healthy infants born at term.
Beyfortus is the first preventive option developed to protect a broad infant population against RSV LRTD, including protecting those infants born ...